]>
IRCT20190303042889N1 IRCT 2021-03-30 Mashhad University of Medical Sciences Evaluation of the effectiveness of complementary therapy with Portulaca oleracea capsule on the clinical symptoms of outpatients with COVID-19 Evaluation of the effectiveness of complementary therapy with Portulaca oleracea capsule on the clinical symptoms of outpatients with COVID-19 2021-05-05 anticipated 70 Complete https://irct.ir/trial/55153 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to allocate individuals in the two groups of 70 people studied, the blocking method will be used and for this purpose, among the given probabilities, four blocks have been randomly selected, which include: 1- ABBA- 2- AABB- 3- BABA-4-BBAA and each patient visited in one of the first or second groups will be entered in the blocks mentioned above, respectively. After completing the four blocks, the allocation of individuals in the study groups starts again from block one to complete the 140 samples required in the study, Blinding description: This study is a clinical trial with two groups of control and intervention in which placebo is used. For blinding the study, drug form would be similar in two groups and the allocation of individuals is based on the block randomization method. The prescribing physician and the patient will not know the type of capsule that was the medication or the placebo. 3 COVID-19. Intervention 1: Intervention group: Receive common treatments and 300 mg of Portulaca Oleracea extract capsules 2 times a day for 7 days. Intervention 2: Control group: Receive common treatments and placebo capsules. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Seyedeh Zhahra HabibianNejad
Mashhad University of Medical Sciences, Azadi square
Mashhad Iran (Islamic Republic of) 9136964795 98 51 38049 Habibiannezhadz971@mums.ac.ir Mashhad University of Medical Sciences scientific Seyedeh Zhahra HabibianNejad
Azadi square, Mashhad University of Medical Science
Mashhad Iran (Islamic Republic of) 9136964795 98 51 38049 Habibiannezhadz971@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Outpatient with COVID-19 Age 18-60 years Patient satisfaction Being alert and lacking organ damage Confirmation of RT-PCR test for SARS-CoV-2 Blood saturated oxygen content more than 90% 18 years 60 years Both Pregnant and lactating women comorbidity End stage Patient U07.1 COVID-19 Treatment - Drugs Placebo Intervention group: Receive common treatments and 300 mg of Portulaca Oleracea extract capsules 2 times a day for 7 days Control group: Receive common treatments and placebo capsules Improvement time of clinical manifestation based on questionnaire. Timepoint: The beginning of the intervention & day 14. Method of measurement: questionnaire. Normalization of CRP and lymphopenia. Timepoint: The beginning of the intervention & day 14. Method of measurement: laboratory. Mashhad University of Medical Sciences Approved 2021-02-27 Ethics committee of Mashhad University of Medical Sciences Mashhad University of Medical Sciences, Azadi Square, Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)